Anti-glycation agents for preventing age-, diabetes-, and smoking-related complications
CA 2463624 A1 · Owner: Lertvorachon, Jittiwud · Inventors: Lertvorachon, Jittiwud; Popek, Tomasz; Kiyota, Taira
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
The invention provides new inhibitors of protein glycation identified from , compound libraries by a high throughput screening assay. The anti-glycation agents so identified are characterized by a variety of chemical structures and are useful for the prevention or treatment of agediabetes-, and smoking-, related complications including neuropathy, nephropathy, ocular pathologies or the loss of mechanical properties of collagenous tissues. Among compounds identified as having the anti-glycation activity of special interest are , epinephrine and its analogs in particular D-epinephrine and its analogs which are particularly useful for the prevention or treatment of agediabetes-, and …
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed October 15, 2002. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended October 15, 2022.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by October 15, 2024.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.